Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,412 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Infusion Clear all
Completed Phase 2 Interventional Results available

AZD9773 Dose Escalation Study

NCT00615017
View directory record Official record
Conditions
Severe Sepsis
Interventions
AZD9773 (CytoFab), Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Newark, Delaware • Bay Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 2, 2026, 4:45 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds

NCT06792474
View directory record Official record
Conditions
Spinal Disease, Anesthesia, Post Operative Pain
Interventions
Lidocaine in Saline, Normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Prevention of Acute Kidney Injury in Cardiac Surgery Patients

NCT00921518
View directory record Official record
Conditions
Kidney Injury
Interventions
0.9% Sodium Chloride (Placebo), Sodium Bicarbonate
Drug
Lead sponsor
Community Medical Center, Scranton, PA
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 2, 2026, 4:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

NCT04633889
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

NCT00783718
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
102
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DISC-3405 in Healthy Volunteers

NCT06050915
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DISC-3405, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Not applicable Interventional Results available

Aldosterone and Glucose Homeostasis

NCT00732160
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aldosterone infusion (A), Vehicle Infusion (V), High Sodium Diet (HS), Low Sodium Diet (LS)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 2, 2026, 4:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Continuous ESP Catheters on Recovery, Pain and Opioid Consumption After Multilevel Spine Surgery

NCT05494125
View directory record Official record
Conditions
Post Operative Pain, Spine Surgery
Interventions
Ropivacaine, Placebo
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 2, 2026, 4:45 AM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 2, 2026, 4:45 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

NCT06825143
View directory record Official record
Conditions
Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions
Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
Procedure · Drug · Combination Product
Lead sponsor
Gary Van Guilder
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gunnison, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 2, 2026, 4:45 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

NCT01110408
View directory record Official record
Conditions
Complicated Urinary Tract Infections or Pyelonephritis
Interventions
Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 2, 2026, 4:45 AM EDT
Not listed Phase 2 Interventional

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

NCT00102908
View directory record Official record
Conditions
HIV Infections, Osteopenia, Osteoporosis
Interventions
Zoledronate, Zoledronate placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Sep 2, 2026, 4:45 AM EDT
Terminated Phase 3 Interventional Results available

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

NCT04160468
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Exebacase, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
12 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 2, 2026, 4:45 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

NCT05568888
View directory record Official record
Conditions
Traumatic Injury
Interventions
BE1116, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
15 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
90
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NCT01243151
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
9
States / cities
Culver City, California • Glendale, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

NCT04506073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

NCT03976362
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Non-small-cell Lung
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Not applicable Interventional

Ketamine for Pain Control After Severe Traumatic Injury

NCT04274361
View directory record Official record
Conditions
Hospital Inpatient Trauma Injury, Pain Management
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 64 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 2, 2026, 4:45 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

NCT00608231
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia
Interventions
Dexmedetomidine Hydrochloride Infusion, Normal Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 2, 2026, 4:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Calcium Chloride for Prevention of Uterine Atony During Cesarean

NCT03867383
View directory record Official record
Conditions
Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
Interventions
Calcium Chloride, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 2, 2026, 4:45 AM EDT